Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 8Lymphoid 3Genitourinary 3Gastrointestinal 2Thoracic 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Prostatic Neoplasms 2Carcinoma, Renal Cell 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × siltuximab × Genitourinary × Clear all
NCT00265135 2014-07-03

A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma

Centocor, Inc.

Phase 1/2 Completed
68 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00401765 2014-05-26

A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Centocor, Inc.

Phase 1 Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT00433446 2013-02-05

S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

SWOG Cancer Research Network

Phase 2 Completed
62 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡